XBIO
Xenetic Biosciences Inc

10,663
Loading...
Loading...
News
all
press releases
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Xenetic Biosciences, Inc. Under Pressure: Shareholder Activism Threatens Stability and Financial Future
Xenetic Biosciences, Inc. (XBIO) has disclosed a new risk, in the Share Price & Shareholder Rights category. Xenetic Biosciences, Inc. faces financ...
TipRanks Financial Blog·2y ago
News Placeholder
Xenetic Biosciences reports FY results
Xenetic Biosciences reports FY results...
SeekingAlpha.com: All News·2y ago
News Placeholder
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the year with...
Accesswire·2y ago
News Placeholder
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 71.7% in January
Xenetic Biosciences Inc (NASDAQ:XBIO Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest...
Zolmax·2y ago
News Placeholder
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platformFRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences...
Accesswire·2y ago

Latest XBIO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.